News

Alba Bioscience Limited and Medline Industries, LP have signed a distribution agreement, which will enable Medline to distribute Alba’s range of reagents in the USA. The distribution agreement takes effect immediately. Alba develops and manufactures high-quality blood bank reagents for the manual testing market. Our extensive range of products is expertly designed to meet the…

Are you facing challenges in achieving accurate, timely diagnoses for patients with suspected autoimmune conditions? Join us for an exclusive webinar where Dr. Gerber Gomez, Scientific & Medical Officer at AliveDx, will share: Date: 13 March 2025 Time: 14h00-15h00 CET Duration: 60 minutes

We are excited to announce that our MosaiQ AiPlex® Celiac Disease (CD) solution has obtained Medical Device Authority (MDA) registration in Malaysia! The registration confirms the safety, quality, and effectiveness of our system. With this approval, AliveDx is now authorized to market and sell the MosaiQ AiPlex CD solution in Malaysia. “We are delighted to…

Alba Bioscience is pleased to have completed the UK National Health Service (NHS) Evergreen Sustainable Supplier Assessment. The Assessment is a self-assessment and reporting tool and resulted in Alba Bioscience receiving a Level 2: Comprehensive net zero targets and reporting for carbon emissions. The information reported through Evergreen is supporting Alba Bioscience to understand its…

We are excited to announce the launch of the AliveDx Scientific Insights Center on the AliveDx website. The Scientific Insights Center provides laboratorians and the medical community access to key published scientific communications. It offers valuable insights to help navigate the complexities of autoimmune and allergy disease diagnostics. Our goal is to empower them with…

AliveDx Suisse S.A. and Sedeer Medical Services and Trading Co. LLC have signed a distribution agreement, which will enable Sedeer to distribute the MosaiQ® and LumiQ™ solutions in Qatar. The distribution agreement takes effect immediately. AliveDx is committed to expanding its global presence and advancing autoimmune diagnostics. Through strategic collaborations, such as this partnership in…

We are excited to announce that our IVDR-CE marked MosaiQ AiPlex® Celiac Disease (CD) system is now available in the EU market and other geographies that recognize the CE mark (pending local registration in some countries). Celiac Disease is a serious autoimmune disorder that affects approximately 1% of the global population. This condition primarily impacts…

AliveDx is dedicated to expanding its reach and presence across diverse regions, with the goal of delivering both clinical and economical value to clinicians by reducing the time to diagnosis for patients suffering from autoimmune and allergy diseases.  We are thrilled to announce that we have multiple customers currently evaluating the MosaiQ system across the…

We are delighted to speak at the upcoming International Friday Meeting on Friday, 6 December 2024 at 6:30AM CET. The International Friday Meeting is a monthly meeting, held on the first Friday of the month, hosted by Pr. Yehuda Shoenfeld. The meeting explores key topics and research breakthroughs in the autoimmunity landscape. The event attracts…

AliveDx Suisse S.A. and Medikonia Limited have signed a distribution agreement, which will enable Medikonia to distribute the MosaiQ® solution in Hong Kong and Macau. The distribution agreement takes effect immediately. AliveDx is committed to broadening its reach and presence across different regions, aiming to generate both clinical and economical value for clinicians, helping them…